Combination of low-dose HBIg and Nucleoside analogues to prevent recurrent hepatitis B virus after liver transplantation: a retrospective analysis of 1506 cases
10.3760/cma.j.issn.1007-8118.2011.05.005
- VernacularTitle:小剂量HBIg联合核苷类似物预防肝移植术后乙肝复发1506例回顾性分析
- Author:
Zhongyang SHEN
;
Zhijun ZHU
;
Yonglin DENG
;
Liying SUN
;
Wei QU
;
Wei RAO
;
Xiaoye SUN
;
Hong ZHENG
;
Cheng PAN
;
Yihe LIU
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Hepatitis B virus;
Recurrence
- From:
Chinese Journal of Hepatobiliary Surgery
2011;17(5):364-366
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the preventive effect of combination of low-dose HBIg and Nucleoside analogues on recurrence of hepatitis B after liver transplantation. Methods Retrospectively analyzed HBV status and recurrence in patients accepting Nucleoside analogues plus low-dose HBIg as prophylaxis treatment after liver transplantation for HBV-related end-stage liver disease from December 1998 to Octomber 2009 in our center. Results In all the 1506 patients whose survival time >30 d after liver transplantation, 37 patients showed HBV recurrence, the HBV cumulative-recurrence rate of 1, 2, 3, 4, 5 and 6y was 1.3%,2. 4%,2. 7%,2. 9%,3. 7% and 4.6% respectively. The time of recurrence varied from 0. 3 to 66. 6 months (median 12. 8 months) after transplantation. Virus mutation could be tested in 9 cases of the 37 recurrence patients, including 4 YMDD cases, 2 YMDD + YIDD cases, 1 YMDD+YVDD cases, 1 YVDD case,and 1 YIDD case. Conclusions Liver transplantation is the principal therapeutic method for the patient with end-stage liver diseases related to HBV, with the effectively prophylaxis treatment to aim directly at HBV recurrence. If the patients who got HBV recurrence received targeted treatments, the situation can be controlled satisfactorily.
